Your session is about to expire
← Back to Search
Device
Novo-TTF for Glioblastoma
N/A
Waitlist Available
Led By Suyash Mohan, Dr.
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial is testing a new way to use MRI to track how well a treatment is working for brain cancer.
Eligible Conditions
- Glioblastoma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Radiological response using standard of care bi monthly MRI scans
Secondary outcome measures
Overall survival (OS)
Progression free survival time
Treatment Response using modified RANO criterion
Trial Design
1Treatment groups
Experimental Treatment
Group I: Methods to identify treatment responseExperimental Treatment1 Intervention
The investigators will study how well these advanced MRI methods are in accurately identifying response to Novo-TTF in comparison to standard MRI methods for evaluation of treatment response. Using advanced MRI imaging techniques may help assess treatment response earlier than changes in tumor volume which can be measured with standard MRI methods.
Find a Location
Who is running the clinical trial?
University of PennsylvaniaLead Sponsor
2,000 Previous Clinical Trials
42,880,058 Total Patients Enrolled
7 Trials studying Glioblastoma
175 Patients Enrolled for Glioblastoma
Abramson Cancer Center at Penn MedicineLead Sponsor
387 Previous Clinical Trials
145,665 Total Patients Enrolled
7 Trials studying Glioblastoma
245 Patients Enrolled for Glioblastoma
Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,065 Total Patients Enrolled
7 Trials studying Glioblastoma
245 Patients Enrolled for Glioblastoma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have signs of increased pressure inside your head, like severe headaches, vomiting, or changes in consciousness.You have recently been diagnosed with or have a recurring form of brain cancer called glioblastoma multiforme (GBM).You should have a Karnofsky scale score of 60 or higher.You are expected to live for at least 3 more months.You need to receive at least 40 Gy (a measurement of radiation) of radiation therapy along with the study treatment.You have had a previous allergic reaction to Temozolomide or DTIC.
Research Study Groups:
This trial has the following groups:- Group 1: Methods to identify treatment response
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger